Physician
Gastroenterology
Dr. Paul J. Pockros, MD
|
|
Give Review
Paul Pockros works in the field of Gastroenterology. She studied medicine at Keck School of Medicine of USC. Keck School of Medicine of USC is ranked 31/72 in Research/PrimaryCare. She over the years received 4 awards: "Fellow (AGAF)", "Fellow (FACG)", "Top MD" and "Super Doctor". Paul Pockros is also a published physician. She has 100 publication published. The most recent publication is: Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group. Paul J. Pockros, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.
- HCV Council - Critical Appraisal of Data: Recommendations for Clinical Practice in a Rapidly Evolving Therapeutic Landscape.
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
- A genome sequencing program for novel undiagnosed diseases.
- Advances in newly developing therapy for chronic hepatitis C virus infection.
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis.
- Simeprevir for the treatment of chronic hepatitis C.
- Drug-induced liver injury from antiepileptic drugs.
- Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease.
- Novel Therapeutic Approaches for Hepatitis C.
- Interferon-free regimens and direct-acting antiviral agents.
- HCV RNA viral load assessments in the era of direct-acting antivirals.
- Nucleoside/Nucleotide analogue polymerase inhibitors in development.
- Non-nucleoside Analogue Polymerase Inhibitors in Development.
- Novel and combination therapies for hepatitis C virus.
- What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?
- JUMP-C: A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients.
- Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.
- Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells.
- Management of patients who are not candidates for protease inhibitor therapy.
- A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth facto...
- Hematologic and oncologic diseases and the liver.
- Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments.
- Why do we need another interferon?
- A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.
- Ribavirin analogs.
- Antifibrotics for chronic hepatitis C.
- Novel therapies in Hepatitis C virus. Preface.
- Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
- Emerging therapies for chronic hepatitis C virus.
- R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
- Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.
- Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis.
- Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or ...
- Noninvasive markers of fibrosis in chronic hepatitis patients.
- Impact of obesity on treatment of chronic hepatitis C.
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
- Helminthic Infections of the Liver.
- Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.
- Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols.
- A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy.
- Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach.
- Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection.
- Comparison of esophageal capsule endoscopy and esophagogastroduodenoscopy for diagnosis of esophageal varices.
- Drugs in development for chronic hepatitis C: a promising future.
- Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
- New direct-acting antivirals in the development for hepatitis C virus infection.
- Drugs in development for viral hepatitis: care and caution.
- Telaprevir for retreatment of HCV infection.
- Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C.
- High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
- Narcotic analgesics and progression of fibrosis in patients with chronic hepatitis C.
- New drugs for hepatitis C virus.
- Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
- Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a.
- Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.
- How should hepatitis C be managed in patients aged 65 years and older?
- Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
- The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA.
- A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.
- An urgency to identify and treat chronic hepatitis C.
- Kinetics of hepatitis C virus reinfection after liver transplantation.
- Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
- SCV-07 (SciClone Pharmaceuticals/Verta).
- Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavir...
- The management of side-effects during therapy for hepatitis C.
- Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
- Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
- Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).
- The safety and tolerability of daily infergen plus ribavirin in the treatment of naÃÂïve chronic hepatitis C patients.
- Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.
- Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
- Risks of a range of alcohol intake on hepatitis C-related fibrosis.
- The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
- Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
- Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
- Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics.
- Focal hemorrhagic necrosis of the liver. A rare cause of hemoperitoneum.
- Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema.
- Toxic megacolon complicating Campylobacter enterocolitis.
- Golytely lavage versus a standard colonoscopy preparation. Effect on normal colonic mucosal histology.
- Acute fatty liver of pregnancy.
- Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG.
- Retinal angiomatosis and pancreatic cysts in von Hippel-Lindau disease: use of computed tomography scanning for diagnosis and surveillance.
- Persistent abnormal liver function without clinical signs or symptoms.
- Idiopathic fatty liver of pregnancy: findings in ten cases.
- Parenteral nutrition complicated by candidiasis.
- Human leukocyte antigen class I-independent pathways may contribute to hepatitis B virus-induced liver disease after liver transplantation.
- Systemic versus nonsystemic reperfusion of the transplanted liver.
- Symptomatic porphyria cutanea tarda and B-immunoblastic lymphoma: is there an association?
- Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection.
- Mutation analysis in hereditary hemochromatosis.
- Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
- Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group.
- Mastocytosis: diverse presentations and outcomes.
- Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group.
- A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. Con...
- Hepatic decompensation in patients with cirrhosis during infection with influenza A.
Doctors Specialties
- Gastroenterology
Accepted Insurances
Awards
- Fellow (AGAF)
- Fellow (FACG)
- Top MD
- Super Doctor
Education
-
Scripps Clinic -
University of Southern California - LAC+USC Medical Center -
Keck School of Medicine of USC
Drug Facts
| NPI NUMBER | 1124082748 | |
| NPPES Provider LastName | POCKROS | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 920371027 | |
| NPPES Provider State | CA | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 1121.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124082748 |
| Last Name Of The Provider | POCKROS |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
Dr. Warren L. Reidel, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Syed M. Fehmi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John M. Lyons Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John G. Kuldau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Docherty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arnold L. Flick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arthur C. Johnson Jr., MD |
|
|
Dr. Ahmad M. Mansour, MD
This Doctor is OpenDoctor Recommended.
|